<DOC>
	<DOCNO>NCT01830647</DOCNO>
	<brief_summary>This prospective observational study evaluate safety efficacy first-line Avastin ( bevacizumab ) combination standard chemotherapy routine clinical practice patient metastatic cancer colon and/or rectum . Patients follow duration treatment 30-day follow-up last dose study drug .</brief_summary>
	<brief_title>An Observational Study Avastin ( Bevacizumab ) Patients With Metastatic Cancer Colon Rectum</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically cytologically confirm carcinoma colon and/or rectum evidence metastasis At least one measurable metastatic lesion ( per RECIST criterion ) Life expectancy &gt; 12 week Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Adequate hematological , renal liver function Prior chemotherapy metastatic disease Clinically significant cardiovascular disease Ongoing treatment aspirin ( 325 mg/day ) medication know predispose gastrointestinal ulceration Participation investigational trial previous 3 month Pregnant lactating woman History thrombotic haemorrhagic disorder Evidence bleed diathesis coagulopathy Uncontrolled hypertension Known hypersensitivity Avastin excipients , chemotherapy Evidence disease disorder contraindicate use investigational drug put patient high risk treatmentrelated complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>